Louis J Lavigne Jr
CIK 1214127 · last filed 2026-06-17
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
AGN price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
2525 DUPONT DRIVE
IRVINE, CA 92612
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALEC | Director | 138,661 | $2.02 | $279.4K | $0 | 9 | 2026-06-17 |
| ZYNGA INC (ZNGA) Delisted | Director | 0 | $8.18 | $0 | $0 | 34 | 2022-05-24 |
| ARAY | Director | 282,329 | $0.13 | $37.0K | $0 | 17 | 2020-12-02 |
| DOCU | Director | 63,888 | $83.34 | $5.32M | $0 | 3 | 2019-06-19 |
| Assertio Therapeutics, Inc (ASRT) Delisted | Director | 972 | $23.50 | $22.8K | $0 | 1 | 2019-05-09 |
| NVCR | Director | 7,403 | $14.42 | $106.8K | $0 | 4 | 2018-06-04 |
| Assertio Therapeutics, Inc (DEPO) Delisted | Director | 4,403 | — | — | $0 | 8 | 2018-05-10 |
| ALLERGAN INC (AGN) Delisted | Director | 18,148 | — | — | -$8.64M | 16 | 2014-12-23 |
| BMC SOFTWARE INC (BMC) Delisted | Director | 29,215 | — | — | $0 | 6 | 2012-07-27 |
| KYPHON INC (KYPH) Delisted | Director | 300 | — | — | $0 | 1 | 2007-08-03 |
Recent Filings · Page 8 of 11
102 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2014-02-24 | ALLERGAN INC (AGN) Delisted | Sell (S) | −5,400 | -$679.2K | EDGAR |
| 2014-02-13 | ALLERGAN INC (AGN) Delisted | Mixed | — | -$3.67M | EDGAR |
| 2013-12-03 | ARAY | Grant (A) | +15,037 | $0 | EDGAR |
| 2013-09-12 | — | Disp (D) | −29,215 | -$1.35M | |
| 2013-07-09 | Assertio Therapeutics, Inc (DEPO) Delisted | Grant (A) | — | $0 | EDGAR |
| 2013-05-02 | ALLERGAN INC (AGN) Delisted | Grant (A) | +3,102 | $0 | EDGAR |
| 2012-12-04 | ARAY | Grant (A) | +19,108 | $0 | EDGAR |
| 2012-08-30 | ALLERGAN INC (AGN) Delisted | Mixed | −15,000 | -$1.28M | EDGAR |
| 2012-07-27 | BMC SOFTWARE INC (BMC) Delisted | Grant (A) | +7,383 | $0 | EDGAR |
| 2012-05-02 | ALLERGAN INC (AGN) Delisted | Grant (A) | +4,800 | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.